Midi Health – an emerging digital leader in women’s midlife healthcare – recently announced the closing of a $25 million Series A funding round led by GV (Google Ventures). And investors Frederique Dame and Cathy Friedman from GV were joined by current investors Felicis, Semper Virens, Icon, 25M, and Operator Collective, bringing the company’s total funding raised to $40 million.
For the year since the company officially launched to consumers, Midi Health already helped tens of thousands of patients and provides care covered by all the major insurance carriers, expanding to 50 states by January 2024. The company will utilize the new funding round to expand operations nationwide and launch additional partnerships with some of the country’s largest hospital systems and major U.S. employers. And Midi Health recently announced a partnership with fertility benefits leader Progyny to bring midlife care to employers across the US. The current employer clients include Stanford University and ServiceNow, and agreements are in place with healthcare systems clients such as Lifepoint Health.
Every day in the U.S., 6,000 women hit menopause, starting 12 months after a woman’s last period. They reach that milestone, on average, at age 51, but perimenopause, the precursor to menopause, can occur much earlier. This lead-up period, when hormones fluctuate wildly and symptoms may be at their worst and most unpredictable, lasts four to seven years. The symptoms – including hot flashes, insomnia, anxiety, depression, brain fog, memory loss, joint pain, and genitourinary problems – significantly impact women’s quality of life and career growth. A recent Mayo Clinic study found that 15% of women cut back on hours or missed work entirely due to their symptoms, costing them about $1.8 billion annually in lost wages.
Midi Health is rapidly expanding its team of clinicians trained in women’s health to address this gap. And they complete a rigorous training program and participate in ongoing education overseen by world-class experts in perimenopause and menopause. The result: A patient’s CSAT score averaged 95 percent.
Every Midi Health patient receives a personalized care plan based on her health history (including any history of breast and other female cancers), genetic risk factors, ethnicity, and race. And care plans are holistic, combining hormonal and non-hormonal prescription medications, behavior change coaching, evidence-based supplements, and integrative therapy recommendations.
KEY QUOTES:
“Midi has seen meaningful traction since its launch and takes an innovative approach to address an unmet need for nearly half the global population. Midi’s world-class executive and advisory team has decades of clinical and healthcare expertise and a vision for personalized, affordable, and accessible midlife care. GV is proud to back Midi as they modernize perimenopause and menopause care for women everywhere.”
- Frederique Dame, General Partner at GV
“It’s clear that menopausal symptoms can derail women’s lives. With far too few practitioners trained in managing menopause, women are underdiagnosed, undertreated, and underserved. Midi provides an insurance-covered solution that focuses on women’s unique needs, closing a major gap in health access, quality, and equity.”
- Midi Health CEO & Founder Joanna Strober
